【用药指导】厄洛替尼一般吃几粒,厄洛替尼的功效和作用

Erlotinib is the first-generation EGFR inhibitor that was first approved by the FDA in 2004 for the treatment of locally advanced or metastatic NSCLC after failure of at least one chemotherapy. In 2006, the drug was approved for marketing in China under the trade name Tarceva. (Erlotinib) Since its launch, global peak sales have reached a sales peak of 1.449 billion Swiss francs. Since then, sales have gradually declined due to the expiration of patents.

Erlotinib's mode of action is different from that of chemotherapy. It is a targeted therapy drug that can specifically target tumor cells and inhibit the formation and growth of tumors. It is a small molecule compound that can inhibit the signaling pathway of the human epidermal growth factor receptor (EGFR); it is a key component of the epidermal growth factor (also known as HER1) signaling pathway and plays an important role in the formation and growth of various tumor cells. Erlotinib inhibits tumor growth by inhibiting the activity of tyrosine kinase, which is one of the important components of EGFR cells.

: This product must be used under the guidance of doctors with experience in the use of such drugs, and can only be used in the national clinical trial pharmacology base or tertiary A hospitals. The recommended dose of erlotinib monotherapy for non-small cell lung cancer is 150 mg/day, taken at least 1 hour before or 2 hours after eating. Continue treatment until disease progression or intolerable toxicity occurs. There is no evidence that patients benefit from continuing treatment after progression. The side effects of Erlotinib with an incidence rate greater than 10% include: rash, diarrhea, loss of appetite, fatigue, dyspnea, cough, nausea, infection, vomiting, stomatitis, itching, dry skin, conjunctivitis, keratoconjunctivitis, and abdominal pain.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.